These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 20376345)
1. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. Kuenzli A; Bucher HC; Anand I; Arutiunov G; Kum LC; McKelvie R; Afzal R; White M; Nordmann AJ PLoS One; 2010 Apr; 5(4):e9946. PubMed ID: 20376345 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
3. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Baker WL; Coleman CI; Kluger J; Reinhart KM; Talati R; Quercia R; Phung OJ; White CM Ann Intern Med; 2009 Dec; 151(12):861-71. PubMed ID: 20008762 [TBL] [Abstract][Full Text] [Related]
4. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? Ahmed A J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029 [TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Kunz R; Friedrich C; Wolbers M; Mann JF Ann Intern Med; 2008 Jan; 148(1):30-48. PubMed ID: 17984482 [TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Lee VC; Rhew DC; Dylan M; Badamgarav E; Braunstein GD; Weingarten SR Ann Intern Med; 2004 Nov; 141(9):693-704. PubMed ID: 15520426 [TBL] [Abstract][Full Text] [Related]
7. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783 [TBL] [Abstract][Full Text] [Related]
9. ACE inhibitors in heart failure: what more do we need to know? Demers C; Mody A; Teo KK; McKelvie RS Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523 [TBL] [Abstract][Full Text] [Related]
10. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. White CM; Greene L J Manag Care Pharm; 2011 Jun; 17(5 Suppl):S1-15. PubMed ID: 21780334 [TBL] [Abstract][Full Text] [Related]
11. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults. Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003 [TBL] [Abstract][Full Text] [Related]
12. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure. Hebert PR; Foody JM; Hennekens CH Curr Vasc Pharmacol; 2003 Mar; 1(1):33-9. PubMed ID: 15320851 [TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery. Hollmann C; Fernandes NL; Biccard BM Anesth Analg; 2018 Sep; 127(3):678-687. PubMed ID: 29381513 [TBL] [Abstract][Full Text] [Related]
15. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA; Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319 [TBL] [Abstract][Full Text] [Related]
16. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931 [TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. Lakhdar R; Al-Mallah MH; Lanfear DE J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both? Cruden NL; Newby DE Am J Cardiovasc Drugs; 2004; 4(6):345-53. PubMed ID: 15554719 [TBL] [Abstract][Full Text] [Related]
19. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154 [TBL] [Abstract][Full Text] [Related]
20. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist? Bangalore S; Kumar S; Messerli FH Congest Heart Fail; 2013; 19(3):107-15. PubMed ID: 23241032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]